Unilife Corp

Unilife — Q1 FY2013 Earnings Presentation

20 slides from Unilife's earnings presentation, Nov 9, 2012

  1. Slide 1: 1st Quarter Earnings Call

    1st Quarter Earnings Call November 8, 2012 NASDAQ (UNIS) and ASX (UNS) Exhibit 99.2

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-lo

  3. Slide 3: Welcome

    Welcome All fundamental areas of Unilife remain fully on track Today's announcement for Unilife bolus injector platform Commercial discussions continue to advance favorably Upcoming supply contracts and clinical development agreements Favorable revenue from multiple programs with multiple customers

  4. Slide 4: Securing an ATM Facility

    Securing an ATM Facility At-The-Market (ATM) facility with Cantor Fitzgerald Strengthens position of Unilife during ongoing commercial negotiations Facility has not been utilized to-date. No immediate intentions to do so Should Unilife elect to draw down on the facility in the future: No discount to

  5. Slide 5: R&D Investment - Key to our Success

    R&D Investment - Key to our Success November 8, 2012 Significant R&D investment across many areas: Customizing existing devices to address specific customer needs Continued pursuit of improving manufacturing efficiencies Development of additional device technologies Each program driven by a specific

  6. Slide 6: LISA Reusable Auto-Injector

    LISA(tm) Reusable Auto-Injector Select Injection Speed Push On Skin Sensor Single Activation Button Easy to Load Needle Free Removal The most advanced auto- injector, with everything a patient needs available at the push of a single button

  7. Slide 7: Unilife Depot-Ject

    Unilife Depot-Ject(tm) Precisely implants a drug depot into the target region of the patient's body using a standard one-handed injection technique

  8. Slide 8: Unilife Ocu-Ject Platform

    Unilife Ocu-Ject(tm) Platform November 8, 2012 Accurate, precise delivery microliter- sized doses to eye Intuitive, ergonomic features minimize pain to patient Optimize compliance with drug labels Prefilled with luer needle Fill at time of use Prefilled with retractable needle Multiple customization

  9. Slide 9: Broad, Expanding Portfolio of Device Platforms

    Broad, Expanding Portfolio of Device Platforms Ongoing R&D Investment

  10. Slide 10: Financial Data Overview

    Financial Data Overview Rich Wieland Chief Financial Officer

  11. Slide 11: Financial Data

    Financial Data 1Q 2013 1Q 2012 Revenues $ 0.7M $ 2.1M Research & development expense $ 4.7M $ 4.3M Selling, general & administrative expense $ 6.6M $ 6.2M Net loss $ 12.5M $ 9.7M Net loss per share - diluted $ (0.16) $ (0.16) Adjusted net loss $ 9.1M $ 6.5M Adjusted net loss per share - diluted $ (0

  12. Slide 12: Improving Operating Expense Efficiencies

    November 8, 2012 18.2% decrease in SG&A and R&D Improving Operating Expense Efficiencies

  13. Slide 13: Commercial Update

    Commercial Update Alan Shortall

  14. Slide 14: Expanded Commercial Development Team

    Expanded Commercial Development Team Michael Ratigan, Senior Vice President and Chief Commercial Officer 23 years of experience with life science and medical device companies Previously Commercial Development Director for Self-Administration of Injectable Systems at BD. Douglas Stout, Senior Directo

  15. Slide 15: Bolus Injectors Targeted for Multi-Drug Program

    Bolus Injectors Targeted for Multi-Drug Program Bolus Injectors Targeted for Multi-Drug Program November 8, 2012 Selected to enter next phase of collaboration with a global pharmaceutical company as its preferred choice for long-term subcutaneous drug delivery under a multi-drug program

  16. Slide 16: Large Dose Volume Bolus Injection Systems

    Large Dose Volume Bolus Injection Systems November 8, 2012 From 1mL - 30mL dose volumes Bolus or Rate-Based Therapies Standard Handling and Materials in Fluid Path Safe, Ergonomic and Intuitive Design Customization Options A flexible, scalable platform of wearable, disposable devices for the subcuta

  17. Slide 17: Program with Global Pharmaceutical Company

    Program with Global Pharmaceutical Company Targeted for Multi-Drug Program More than 5 target pipeline drugs First target in Phase III clinical trials Commenced initial device supply $10MM development agreement for 1st drug expected this fiscal year Expected commercial supply in 2015 Expected annual

  18. Slide 18: Looking Forward

    Looking Forward Targeted Delivery Systems Prefilled Syringes with Integrated Safety Drug Reconstitution Delivery Systems Auto-Injectors Bolus Injectors and Infusion Pumps Active commercial discussions occurring across all platforms Firm opportunities for agreements in all platforms 2012 - 2013

  19. Slide 19: Questions

    Questions November 8, 2012

  20. Slide 20: Reminder: Annual Meeting of Stockholders

    Reminder Annual Meeting of stockholders on Thursday November 29 at 4:00pm at the Intercontinental Barclay Hotel, New York All stockholders and CDI holders invited to attend Also broadcast on Unilife website as a 'live' listen only webcast Eligible stockholders should be receiving notice with instruc

Unilife — Q1 FY2013 Earnings Presentation on 6ix